Emcure Pharmaceuticals (EMCURE) — Financial Results

📢 Key Event
Emcure reported Q1 FY27 revenue of ₹25,804 crores, up 22.8% YoY.

🔄 What Changed
PAT margin increased 110 bps to 11.3%; international revenue share rose to 58%; EBITDA margin improved 50 bps.

🔮 What's Next
Management highlighted continued growth in international markets and expansion of the MASH indication pipeline.

💡 Investor Takeaway
The quarter shows robust top-line growth and improving profitability, supported by international expansion and operational efficiencies.

Emcure Pharmaceuticals reported Q1 FY27 revenue of ₹25,804 crores, up 22.8% YoY, driven by 34.2% international growth and 10.2% domestic expansion. EBITDA margin improved 50 bps to 19.7%, while PAT margin rose 110 bps to 11.3%, reflecting strong operational efficiency and international contribution now representing 58% of revenue.

📄 View Original Announcement (PDF)

📊 Stock Analysis — EMCURE ✨ Ask AI About This

About Emcure Pharmaceuticals Limited (EMCURE)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹35,214.12 Cr P/E: 34.8 ROE: 22.9% ROCE: 29.7% Div Yield: 0.19%

View full EMCURE stock details →

📡 Get AI alerts when EMCURE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track EMCURE — Free

💡 Ask AI about this filing

"How does international revenue growth compare to peers?" "What is the expected PAT margin trajectory for FY27?" "When will the new MASH product launch?"

Ask AI Free →

📊 More EMCURE filings

See all EMCURE filings →

🔥 Also filed on 6 August 2026

CHAMBLFERT Chambal Fertilizers & Chemicals Limited Financial Results SUMEETINDS Sumeet Industries Limited Financial Results VISAKAIND Visaka Industries Limited Corporate Action VISAKAIND Visaka Industries Limited Corporate Action SUNPHARMA Sun Pharmaceutical Industries Limited Financial Results VSTL Vibhor Steel Tubes Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when EMCURE files new disclosures

Track EMCURE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track EMCURE — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd